Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy

Nitrogen‐bisphosphonates (n‐BP), often referred to as aminobisphosphonates, are the most commonly prescribed drugs for the treatment of disorders of bone fragility. However, long‐term continuous treatment predisposes certain individuals to serious rare side effects, such as bisphosphonate‐associated osteonecrosis of the jaw (BAONJ). n‐BP use is known to unintentionally activate a subset of innate T cells called Vγ9Vδ2 T cells, but the consequence of this chronic immune stimulation has remained unexplored. The primary objectives of this study were to 1) determine the fate of Vγ9Vδ2 T cells in osteoporotic patients on n‐BP therapy as a function of time and type of therapy; 2) evaluate the proportion of Vγ9Vδ2 T cells in patients who had recently experienced n‐BP–associated ONJ. We found there is a notable loss of Vγ9Vδ2 T cells over time in osteoporotic patients on n‐BP therapy, particularly those on intravenous (iv) therapy (Spearman r = −0.55, p < 0.0001 iv; r = −0.3, p < 0.03 oral) (n = 68); no difference was observed in total T cells, monocytes, or granulocytes. Importantly, the observed negative effect on Vγ9Vδ2 T cells coincides with the reported route of administration and timing of the rare occurrence of BAONJ. Patients (n = 6) who had experienced BAONJ were all found to be significantly deficient in Vγ9Vδ2 T cells (median = 0.07%) in comparison to age‐ and sex‐matched treatment‐naïve controls (N = 11; median = 2.40%), U = 0, p = 0.001; this was the only consistent difference in the leukocytes assessed. All BAONJ cases had an underlying condition that further contributed to impaired immunity. We propose Vγ9Vδ2 T cells show a strong potential to serve as harbingers of possible adverse immune effects of n‐BP therapy, particularly in those patients already having a compromised immune system as they may be most vulnerable to the development of conditions such as BAONJ. © 2013 American Society for Bone and Mineral Research.

[1]  S. Adami,et al.  Circulating γδ T cells and the risk of acute‐phase response after zoledronic acid administration , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  D. Kabelitz,et al.  Aminobisphosphonates and Toll-like receptor ligands: recruiting Vγ9Vδ2 T cells for the treatment of hematologic malignancy. , 2011, Current medicinal chemistry.

[3]  M. Todaro,et al.  In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low‐dose interleukin‐2 for immunotherapy of advanced breast cancer patients , 2010, Clinical and experimental immunology.

[4]  D. Kabelitz Human γδ T lymphocytes for immunotherapeutic strategies against cancer , 2010, F1000 medicine reports.

[5]  G. H. Nancollas,et al.  Fluorescent Risedronate Analogues Reveal Bisphosphonate Uptake by Bone Marrow Monocytes and Localization Around Osteocytes In Vivo , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  A. Zavras,et al.  Bisphosphonates and time to osteonecrosis development. , 2009, The oncologist.

[7]  G. Laurent,et al.  Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. , 2009, Blood.

[8]  B. Jobke Giant osteoclast formation and long-term oral bisphosphonate therapy. , 2009, The New England journal of medicine.

[9]  J. Mönkkönen,et al.  Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP , 2009, British journal of haematology.

[10]  I. Reid Osteonecrosis of the jaw: who gets it, and why? , 2009, Bone.

[11]  Dennis P. West,et al.  Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. , 2008, The Lancet. Oncology.

[12]  C. Shuler,et al.  Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[13]  S. Wimalawansa Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. , 2008, Expert opinion on drug safety.

[14]  S. Silverman,et al.  Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[15]  C. Smith,et al.  gamma delta T cells are necessary for platelet and neutrophil accumulation in limbal vessels and efficient epithelial repair after corneal abrasion. , 2007, The American journal of pathology.

[16]  M. Rogers,et al.  Molecular Mechanisms of Action of Bisphosphonates: Current Status , 2006, Clinical Cancer Research.

[17]  D. Costagliola,et al.  Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy , 2006, AIDS.

[18]  L. Elting,et al.  Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. , 2006, The Lancet. Oncology.

[19]  A. Chow,et al.  Human Peripheral γδ T Cells Potentiate the Early Proinflammatory Cytokine Response to Staphylococcal Toxic Shock Syndrome Toxin-1 , 2004 .

[20]  A. Chow,et al.  Human peripheral gammadelta T cells potentiate the early proinflammatory cytokine response to staphylococcal toxic shock syndrome toxin-1. , 2004, The Journal of infectious diseases.

[21]  R. Braun,et al.  Human γδ-T Lymphocytes Express and Synthesize Connective Tissue Growth Factor: Effect of IL-15 and TGF-β1 and Comparison with αβ-T Lymphocytes1 , 2003, The Journal of Immunology.

[22]  F. Poccia,et al.  Hiv-mediated γδ T cell depletion is specific for vγ2+ cells expressing the Jγ1.2 segment , 2003 .

[23]  F. Poccia,et al.  HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment. , 2003, AIDS research and human retroviruses.

[24]  R. Braun,et al.  Human gamma delta-T lymphocytes express and synthesize connective tissue growth factor: effect of IL-15 and TGF-beta 1 and comparison with alpha beta-T lymphocytes. , 2003, Journal of immunology.

[25]  Lisheng Wang,et al.  Human Vγ2Vδ2 T Cells Augment Migration-Inhibitory Factor Secretion and Counteract the Inhibitory Effect of Glucocorticoids on IL-1β and TNF-α Production1 , 2002, The Journal of Immunology.

[26]  E. Fuchs,et al.  A Role for Skin γδ T Cells in Wound Repair , 2002, Science.

[27]  Lisheng Wang,et al.  Human V gamma 2V delta 2 T cells augment migration-inhibitory factor secretion and counteract the inhibitory effect of glucocorticoids on IL-1 beta and TNF-alpha production. , 2002, Journal of immunology.

[28]  E. Gelfand,et al.  γδ T Cells as Regulators of Airway Hyperresponsiveness , 2001, International Archives of Allergy and Immunology.

[29]  Y. Gan,et al.  Fas-dependent, activation-induced cell death of gammadelta cells. , 2001, Journal of biological regulators and homeostatic agents.

[30]  Yoshimasa Tanaka,et al.  Essential Requirement of Antigen Presentation by Monocyte Lineage Cells for the Activation of Primary Human γδ T Cells by Aminobisphosphonate Antigen1 , 2001, The Journal of Immunology.

[31]  E. Gelfand,et al.  gammadelta T cells as regulators of airway hyperresponsiveness. , 2001, International archives of allergy and immunology.

[32]  N. Minato,et al.  Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. , 2001, Journal of immunology.

[33]  S. Carding,et al.  Downmodulation of the Inflammatory Response to Bacterial Infection by γδ T Cells Cytotoxic for Activated Macrophages , 2000, The Journal of experimental medicine.

[34]  S. Carding,et al.  The importance of gd T cells in the resolution of pathogen‐induced inflammatory immune responses , 2000 .

[35]  D. Witherden,et al.  A role for epithelial gamma delta T cells in tissue repair. , 2000, Springer seminars in immunopathology.

[36]  S. Carding,et al.  The importance of gamma delta T cells in the resolution of pathogen-induced inflammatory immune responses. , 2000, Immunological reviews.

[37]  M. Wilhelm,et al.  Gamma/delta T-cell stimulation by pamidronate. , 1999, The New England journal of medicine.

[38]  P. Campbell,et al.  Immune protection and control of inflammatory tissue necrosis by gamma delta T cells. , 1994, Journal of immunology.

[39]  M. Bonneville,et al.  Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. , 1994, Science.